PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Company Overview - PTC Therapeutics is expected to report a quarterly loss of $0.96 per share, reflecting a year-over-year change of -300$252.51 million, down 17.8% from the same quarter last year [3] Earnings Expectations - The earnings report is scheduled for release on February 27, 2025, and could influence stock movement based on actual results compared to estimates [2] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] Earnings Surprise Prediction - The Most Accurate Estimate for PTC Therapeutics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +12.84%, suggesting a bullish outlook from analysts [10] - The stock currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [11] Historical Performance - In the last reported quarter, PTC Therapeutics was expected to post a loss of $1.54 per share but delivered a loss of$1.39, resulting in a surprise of +9.74% [12] - Over the past four quarters, the company has beaten consensus EPS estimates two times [13] Industry Context - Editas Medicine, another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post a loss of $0.39 per share, indicating a year-over-year change of -69.6$37.87 million, down 36.9% from the previous year [17]